Momelotinib has greater anemia-related benefits in myelofibrosis
Momelotinib was associated with greater anemia-related benefits in patients with myelofibrosis, according to an analysis presented at the 12th Annual Meeting of the
Meeting News
Meeting News
Meta-Analysis Investigates Daratumumab-Integrated Quadruple Therapy for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma
A meta-analysis suggests that incorporating daratumumab into standard triplet therapy for newly diagnosed, transplant-eligible patients with multiple myeloma (MM) is associated with higher
Meeting News
High ‘Clinical Burden’ Despite Therapy Advances in Heavily Pretreated Patients With Relapsed Or Refractory Myeloma
Despite advancements in treatment options for relapsed or refractory multiple myeloma (MM), heavily pretreated patients continue to face significant clinical challenges, according to
Meeting News
Poster Winners Awarded at 12th Annual SOHO Meeting
Six poster winners were announced during Poster Session and Reception on Wednesday, September 4, at the Twelfth Annual Meeting of the Society of
Myelodysplastic Syndromes
NCCN Updates MDS Treatment Guidelines to Include Imetelstat Recommendations
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for myelodysplastic neoplasms (MDS) to recommend imetelstat for treating symptomatic anemia
Multiple Myeloma
BVd Outperforms DVd in Phase III DREAMM 7 study
Belantamab mafodotin, bortezomib, and dexamethasone (BVd) treatment showed “significant benefit” in progression-free survival (PFS) when compared with daratumumab, bortezomib, and dexamethasone (DVd) in
Meeting News
Video Interviews
Drs. Shah, Jain Discuss CAR-T Cell Therapy Advances at SOHO 2024
In this video interview from the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO), Bijal Shah, MD, of the Moffitt Cancer
Lymphoma
Indolent B-Cell Lymphomas
US FDA approves epcoritamab for relapsed or refractory follicular lymphoma
The US Food and Drug Administration (FDA) has approved epcoritamab-bysp (EPKINLY) for the treatment of adults with relapsed or refractory follicular lymphoma after
Multiple Myeloma
FDA approves daratumumab plus hyaluronidase – based quadruplet therapy
The US Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for